Lisata Therapeutics (LSTA) Enterprise Value (2016 - 2025)
Lisata Therapeutics (LSTA) has disclosed Enterprise Value for 12 consecutive years, with -$19.3 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 2.59% year-over-year to -$19.3 million, compared with a TTM value of -$19.3 million through Sep 2025, up 2.59%, and an annual FY2024 reading of -$10.9 million, up 52.44% over the prior year.
- Enterprise Value was -$19.3 million for Q3 2025 at Lisata Therapeutics, down from -$12.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$10.9 million in Q4 2024 and bottomed at -$32.7 million in Q3 2023.
- Average Enterprise Value over 3 years is -$21.7 million, with a median of -$22.1 million recorded in 2024.
- The sharpest move saw Enterprise Value fell 19.22% in 2024, then soared 56.66% in 2025.
- Year by year, Enterprise Value stood at -$22.8 million in 2023, then surged by 52.44% to -$10.9 million in 2024, then tumbled by 77.16% to -$19.3 million in 2025.
- Business Quant data shows Enterprise Value for LSTA at -$19.3 million in Q3 2025, -$12.4 million in Q2 2025, and -$17.6 million in Q1 2025.